Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Description
There is still a need for safe, efficient, and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a live
